SNORA62: A Potential Drug Target and Biomarker (G6044)

Target Name: SNORA62

NCBI ID: G6044

Other Name(s): RNU108 | small nucleolar RNA, H/ACA box 62 | Small nucleolar RNA, H/ACA box 62 | E2-1 | E2 | RNE2

SNORA62: A Potential Drug Target and Biomarker

SNORA62 (RNU108) is a small non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of gene expression in the brain and has been shown to play a role in a variety of neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia.

SNORA62 is a RNA-protein hybrid that consists of 198 amino acid residues. It is expressed in a variety of tissues, including brain, heart, and testes, and has been shown to play a role in regulating gene expression in these tissues. It is highly expressed in the brain and has been shown to be involved in the regulation of protein synthesis, cell survival, and neurotransmitter release.

One of the most promising aspects of SNORA62 is its potential as a drug target. Its unique structure and the fact that it is expressed in the brain make it an attractive target for small molecules that can modulate its activity. Several studies have shown that SNORA62 can be modulated by small molecules, including inhibitors of tyrosine kinase, which is a family of enzymes that regulate protein synthesis. These studies suggest that SNORA62 may be an effective target for treating neurological and psychiatric disorders.

In addition to its potential as a drug target, SNORA62 has also been shown to be a potential biomarker. Its expression is affected by a variety of factors, including disease status, treatment, and environmental factors. This makes it an attractive candidate for use as a diagnostic or therapeutic target. Several studies have shown that SNORA62 can be used as a biomarker for a variety of neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia.

The potential of SNORA62 as a drug target and biomarker is significant. Given its unique structure and its expression in the brain, it is an attractive target for small molecules that can modulate its activity. Further research is needed to fully understand its potential and to develop safe and effective treatments for the disorders that it is associated with.

Protein Name: Small Nucleolar RNA, H/ACA Box 62

More Common Targets